CVS · 8-K · 20260805PR000097
Cash Flow and Liquidity
CVS HEALTH Corp · 2026-08-05 · Importance 56 · Surprise 46 · From source text
Cash flow from operations reached $10.594 billion in the first six months of 2026, up from $6.453 billion in the prior-year period. Cash and cash equivalents increased to $11.329 billion at June 30, 2026 from $8.453 billion at December 31, 2025, while total cash, cash equivalents, and restricted cash ended at $11.537 billion. The company generated $2.200 billion from changes in operating assets and liabilities during the first six months. Six-month investing cash outflow was $2.758 billion, including $1.540 billion of property and equipment purchases, while financing cash outflow was $5.011 billion.
Key facts
- Raised full-year 2026 cash flow from operations guidance to at least $11.5 billion from at least $9.5 billion source
- Consolidated six months net cash provided by operating activities: $10,594 million for six months ended June 30, 2026 versus $6,453 million in 2025 source
- Cash and cash equivalents on balance sheet as of June 30, 2026: $11,329 million versus $8,453 million at December 31, 2025 source
- Net cash used in financing activities for six months ended June 30, 2026: $5,011 million versus $1,526 million in 2025 source
- Generated year-to-date cash flow from operations of $10.6 billion source
- Cash, cash equivalents and restricted cash at end of period June 30, 2026: $11,537 million source
- Accounts receivable, net at June 30, 2026: $40,309 million source
- Inventories at June 30, 2026: $17,622 million versus $19,246 million at December 31, 2025 source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | positive | committed | — | Raised full-year 2026 cash flow from operations guidance to at least $11.5 billion from at least $9.5 billion |
| cash | positive | realized | — | Consolidated six months net cash provided by operating activities: $10,594 million for six months ended June 30, 2026 versus $6,453… |
| cash | positive | realized | — | Cash and cash equivalents on balance sheet as of June 30, 2026: $11,329 million versus $8,453 million at December 31, 2025 |
| cash | negative | realized | — | Net cash used in financing activities for six months ended June 30, 2026: $5,011 million versus $1,526 million in 2025 |
| cash | positive | realized | — | Generated year-to-date cash flow from operations of $10.6 billion |
| cash | unclear | realized | — | Cash, cash equivalents and restricted cash at end of period June 30, 2026: $11,537 million |